



Select Publications

- Attal M et al. **Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial.** *Proc International Myeloma Workshop 2011.* No abstract available
- Boyd K et al. **Does zoledronic acid reduce skeletal-related events and improve progression-free survival in patients with multiple myeloma with or without bone disease? MRC Myeloma IX study results.** *Proc ASCO 2011;Abstract 8010.*
- Davies F et al. **Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX trial.** *Proc ASCO 2011;Abstract 8011.*
- Dimopoulos MA et al. **Lenalidomide and dexamethasone (LEN + DEX) treatment in relapsed/refractory multiple myeloma patients and risk of second primary malignancies (SPM): Analysis of MM-009/10.** *Proc ASCO 2011;Abstract 8009.*
- Jakubowiak AJ et al. **Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: Initial results of Phase I/II MMRC trial.** *Proc ASH 2010;Abstract 862.*
- Lacy M et al. **Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease.** *Proc ASH 2010;Abstract 863.*
- Leleu X et al. **Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.** *IFM 2009-02. Proc ASH 2010;Abstract 859.*
- Lonial S et al. **Up-front management of multiple myeloma.** *Oncology 2010;24(12 Suppl 5):8-14.* Available at <http://www.researchtopractice.com/Oncology110>.
- McCarthy P et al. **Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104.** *Proc International Myeloma Workshop 2011.* No abstract available
- Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol 2011;12(5):431-40.* Abstract
- Palumbo A, Anderson K. **Multiple myeloma.** *N Engl J Med 2011;364(11):1046-60.* No abstract available
- Palumbo AP et al. **Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial.** *J Clin Oncol 2010;28(34):5101-9.* Abstract

Palumbo AP et al. **Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma (MM) patients ≥ 65 years.** *Proc ASCO* 2010;Abstract 8007.

Palumbo AP et al. **A Phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.** *Proc ASCO* 2009;Abstract 8515.

Rajkumar SV. **Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.** *Am J Hematol* 2011;86(1):57-65. Abstract

Richardson PGG et al. **Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized Phase 1/2 study.** *Proc ASCO* 2011;Abstract 8014.

Rossi A et al. **Incidence of second primary malignancies (SPM) after 6 years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM).** *Proc ASCO* 2011;Abstract 8008.

Siegel DS et al. **PX-171-003-A1, an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma: Long-term follow-up and subgroup analysis.** *Proc ASCO* 2011;Abstract 8027.

Stewart AK et al. **The effect of carfilzomib (CFZ) in patients with bortezomib (BTZ)-naïve relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study.** *Proc ASCO* 2011;Abstract 8026.

Wang M et al. **Interim results from PX-171-006, a Phase II multicenter dose-expansion study of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed and/or refractory multiple myeloma.** *Proc ASCO* 2011;Abstract 8025.

Phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. NCT01080391.

Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (IFM/DFCI2009). NCT01208662.